Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

Phase 2 Active not recruiting 102 enrolled Daewoong Pharmaceutical Co. LTD.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.

Timeline

Start: 2022-07-29
Primary completion: 2026-10-13
Completion: 2027-01-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BERSIPOROCIN	Small molecule	—	—

Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

Summary

Timeline

Drugs

Indications